1. miR-15a and 16-1 are downregulated in CD4+ T cells of multiple sclerosis relapsing patients.
- Author
-
Lorenzi JC, Brum DG, Zanette DL, de Paula Alves Souza A, Barbuzano FG, Dos Santos AC, Barreira AA, and da Silva WA
- Subjects
- Adult, CD8-Positive T-Lymphocytes metabolism, Case-Control Studies, Cell Proliferation, Disability Evaluation, Female, Humans, Lymphocyte Activation immunology, Male, MicroRNAs genetics, Proto-Oncogene Proteins c-bcl-2 metabolism, RNA, Messenger metabolism, Young Adult, CD4-Positive T-Lymphocytes metabolism, Down-Regulation immunology, MicroRNAs metabolism, Multiple Sclerosis, Relapsing-Remitting genetics, Multiple Sclerosis, Relapsing-Remitting immunology, Multiple Sclerosis, Relapsing-Remitting metabolism
- Abstract
The pathology of relapsing-remitting multiple sclerosis (RR-MS) is largely attributed to activated autoreactive effector T lymphocytes. The influence of microRNAs on the immune response has been shown to occur in different pathways of lymphocyte differentiation and function. Here, the expression of the miRNAs miR-15a/16-1 in PBMC, CD4(+), and CD8(+) from RR-MS patients has been investigated. BCL2, a known miR-15a/16-1 target, has also been analyzed. The results have shown that miR-15a/16-1 is downregulated in CD4(+) T cells, whereas BCL2 is highly expressed in RR-MS patients only. Our data suggest that miR-15a/16-1 can also modulate the BCL2 gene expression in CD4(+) T cells from RR-MS patients, thereby affecting apoptosis processes.
- Published
- 2012
- Full Text
- View/download PDF